BioPharma DiveOriginal article
Beacon eye gene therapy hits mark in late-stage study
Phase 3positivePositive
AI Analysis
Summary
Beacon's eye gene therapy met its primary endpoint in a late-stage pivotal trial for X-linked retinitis pigmentosa, marking the first treatment for this rare blinding condition to achieve this milestone.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary endpoint in pivotal trial for X-linked retinitis pigmentosa
Importance:7/10
Sentiment:
0.85
rare_diseasegene_therapyophthalmologypivotal_trial
Related Companies
Read the original article
Published by BioPharma Dive on September 21, 2026 6:59 PM